Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1940 1
1946 1
1948 1
1951 1
1952 2
1955 1
1956 2
1959 1
1961 1
1962 1
1963 2
1964 3
1965 2
1966 2
1967 3
1968 2
1969 2
1970 3
1971 5
1972 5
1973 6
1974 1
1975 2
1976 2
1978 4
1980 1
1981 2
1982 1
1983 1
1985 2
1986 1
1988 2
2007 1
2020 1
2021 1
2022 2
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

71 results

Results by year

Filters applied: . Clear all
Page 1
Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort study.
Liu Z, Le K, Zhou X, Alexander JL, Lin S, Bewshea C, Chanchlani N, Nice R, McDonald TJ, Lamb CA, Sebastian S, Kok K, Lees CW, Hart AL, Pollok RC, Boyton RJ, Altmann DM, Pollock KM, Goodhand JR, Kennedy NA, Ahmad T, Powell N; CLARITY study investigators. Liu Z, et al. Lancet Gastroenterol Hepatol. 2023 Feb;8(2):145-156. doi: 10.1016/S2468-1253(22)00389-2. Epub 2022 Dec 5. Lancet Gastroenterol Hepatol. 2023. PMID: 36481043 Free PMC article.
Treatment adaptations and outcomes of patients experiencing inflammatory bowel disease flares during the early COVID-19 pandemic: the PREPARE-IBD multicentre cohort study.
Saifuddin A, Kent AJ, Mehta SJ, Hicks LC, Gonzalez HA, Segal JP, Brookes MJ, Subramanian S, Bhala N, Conley TE, Patel KV; PREPARE-IBD Collaborators; Lamb CA, Walker GJ, Kennedy NA, Sebastian S. Saifuddin A, et al. Aliment Pharmacol Ther. 2022 Nov;56(10):1460-1474. doi: 10.1111/apt.17223. Epub 2022 Oct 5. Aliment Pharmacol Ther. 2022. PMID: 36196569 Free PMC article.
Comparative effectiveness of ustekinumab or vedolizumab after one year in 130 patients with anti-TNF-refractory Crohn's disease.
Townsend T, Razanskaite V, Dodd S, Storey D, Michail S, Morgan J, Davies M, Penman D, Watters C, Swaminathan M, Sabine J, Chapman A, Smith PJ, Flanagan PK, Reilly I, Bodger K, Subramanian S. Townsend T, et al. Among authors: sabine j. Aliment Pharmacol Ther. 2020 Oct;52(8):1341-1352. doi: 10.1111/apt.16057. Epub 2020 Sep 10. Aliment Pharmacol Ther. 2020. PMID: 32955122
ACETATE METABOLISM IN THE RUMINANT.
SABINE JR, JOHNSON BC. SABINE JR, et al. J Biol Chem. 1964 Jan;239:89-93. J Biol Chem. 1964. PMID: 14114878 Free article. No abstract available.
3- -Hydroxysterol synthesis by the liver.
Brunengraber H, Sabine JR, Boutry M, Lowenstein JM. Brunengraber H, et al. Among authors: sabine jr. Arch Biochem Biophys. 1972 Jun;150(2):392-6. doi: 10.1016/0003-9861(72)90054-9. Arch Biochem Biophys. 1972. PMID: 5044033 No abstract available.
Physiotherapy for chest conditions.
SABINE J. SABINE J. Physiotherapy. 1946 Jun;31:154-7. Physiotherapy. 1946. PMID: 20985505 No abstract available.
71 results